|
Status
|
Discontinued
|
|
Decision
|
Selected
|
| Process |
MTA
|
| Referral date |
01 October 2000 |
|
Topic area
|
- Blood and immune system
- Cardiovascular
- Diagnostic procedures
- Therapeutic procedures
|
Provisional Schedule
| Consultation on draft scope by stakeholders: |
June 2006 |
|
| Information meeting with consultees: |
11 October 2006 |
| Closing date for invited submissions / evidence submission: |
29 November 2006 |
| Final scope published: |
August 2006 |
| 1st appraisal committee meeting: |
30 May 2007 |
| 2nd appraisal committee meeting: |
25 July 2007 |
Project Team
| Assessment Group / Evidence Review Group: |
School of Health & Related Research, University of Sheffield |
| Communications manager: |
Phil Ranson |
| Executive Lead: |
Gillian Leng |
| Project manager: |
Eloise Saile |
| Technical Lead: |
Eleanor Donegan |
Stakeholders
| Manufacturers/sponsors |
GlaxoSmithKline (eltrombopag) |
| Others |
Department of Health |
| |
Welsh Assembly Government |
| Patient/carer groups |
ITP Support Association |
| Professional groups |
British Society for Haematology |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| Associated guideline groups |
None |
| Associated public health groups |
None |
| Comparator manufacturers |
Roche Products (mycophenolate mofetil, rituximab) |
| |
Sanofi-aventis (danazol) |
| Evidence review groups |
Aberdeen HTA Group |
| |
National Institute for Health Research Health Technology Assessment Programme |
| General |
NHS Quality Improvement Scotland |
| Relevant research groups |
None |
|
Date
|
Update
|
|
13 July 2007
|
The Committee met on the 30 May 2007 to consider the evidence for this appraisal. On this occasion we were not able to issue an Appraisal Consultation Document (ACD) following the meeting. We will update you shortly once we have determined the best way to progress this appraisal. |
|
July 2008
|
This topic has been removed from NICE’s Technology Appraisal work programme, following receipt of confirmation from Minister. |
For further information on our processes and methods, please see our CHTE processes and methods manual